Financial Architects (New Jersey)’s Clovis Oncology, Inc. CLVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-450
Closed -$11K – 1538
2019
Q1
$11K Hold
450
– – ﹤0.01% 1072
2018
Q4
$8K Hold
450
– – ﹤0.01% 1050
2018
Q3
$13K Hold
450
– – ﹤0.01% 1052
2018
Q2
$20K Hold
450
– – ﹤0.01% 814
2018
Q1
$24K Buy
450
+350
+350% +$20.4K ﹤0.01% 837
2017
Q4
$7K Buy
+100
New +$6.99K ﹤0.01% 1238
2017
Q2
– Sell
-300
Closed -$19K – 1667
2017
Q1
$19K Buy
+300
New +$18.2K ﹤0.01% 955
2016
Q4
– Sell
-100
Closed -$4K – 1533
2016
Q3
$4K Buy
+100
New +$2.15K ﹤0.01% 1216
2015
Q3
– Sell
-2,000
Closed -$176K – 994
2015
Q2
$176K Buy
+2,000
New +$171K 0.06% 211

Other funds holding CLVS

Financial Architects (New Jersey)'s CLVS Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 450 shares — an estimated $11K sold.

Financial Architects (New Jersey) first reported a position in CLVS in Q2 2015 and held it in 9 quarters. The position peaked at $176K in Q2 2015. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Financial Architects (New Jersey) reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 450 Clovis Oncology, Inc. shares in Q2 2019, an estimated $11K.
  • Financial Architects (New Jersey) first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 9 quarters.
  • Financial Architects (New Jersey)'s Clovis Oncology, Inc. position peaked at $176K in Q2 2015.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.